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Background and purpose: Inflammatory bowel disease (IBD) is associated with activation of nuclear factor kappa B (NF-kB)
involved in regulating the expression of inducible nitric oxide synthase (iNOS) and proinflammatory cytokine genes. As
theaflavin-3,30-digallate (TFDG), the most potent anti-oxidant polyphenol of black tea, down-regulates NF-kB activation, we
investigated if TFDG is beneficial in colonic inflammation by suppressing iNOS and proinflammatory cytokines.
Experimental approach: The in vivo efficacy of TFDG was assessed in mice with trinitrobenzene sulfonic acid (TNBS)-induced
colitis. Both mRNA and protein levels of proinflammatory cytokines and iNOS were analyzed in colon tissue treated with or
without TFDG. NF-kB activation was determined by electrophoretic mobility shift assay and levels of NF-kB inhibitory protein
(IkBa) were analyzed by Western blotting.
Key results: Oral administration of TFDG (5 mg kg1 daily i.g.) significantly improved TNBS-induced colitis associated with
decreased mRNA and protein levels of TNF-a, IL-12, IFN-g and iNOS in colonic mucosa. DNA binding and Western blotting
revealed increase in NF-kB activation and IkBa depletion in TNBS-treated mice from Day 2 through Day 8 with a maximum at
Day 4, which resulted from increased phosphorylation of IkBa and higher activity of IkB kinase (IKK). Pretreatment with TFDG
markedly inhibited TNBS-induced increases in nuclear localization of NF-kB, cytosolic IKK activity and preserved IkBa in colon
tissue.
Conclusions and Implications: TFDG exerts protective effects in experimental colitis and inhibits production of inflammatory
mediators through a mechanism that, at least in part, involves inhibition of NF-kB activation.
British Journal of Pharmacology (2006) 149, 121–131. doi:10.1038/sj.bjp.0706847; published online 31 July 2006
Keywords: inflammatory bowel disease; theaflavin-3-30-digallate; TNBS-induced colitis; nuclear factor kB; proinflammatory
cytokine; inducible nitric oxide synthase
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; iNOS, inducible nitric oxide synthase; NF-kB, nuclear
factor kappa B; IkBa, NF-kB inhibitory protein; IKK, IkB kinase; TFDG, theaflavin-3,30-digallate; TFD1,
theaflavin-3-gallate; TFD2, theaflavin-30-gallate; TNBS, 2,4,6-trinitrobenzene sulfonic acid; TR, thearubigin;
UC, ulcerative colitis
Introduction
Inflammatory bowel disease (IBD), comprising two major
disease entities, Crohn’s disease (CD) and ulcerative colitis
(UC) and identifiable by a set of clinical, endoscopic and
histological features (Kirsner and Shorter, 1988) is of still
unknown aetiology. In most of the chronic inflammatory
diseases, adhesion molecules recruit inflammatory cells,
such as neutrophils, eosinophils and T lymphocytes, from
the circulation to the site of inflammation (Albelda et al.,
1994). In a majority of animal models of intestinal
inflammation, including the well-characterized hapten
reagent 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced
colitis model, increased levels of mucosal proinflammatory
cytokines such as IL-1b, IL-6, TNF-a, IL-12 and IFN-g have
been shown to play an important role in sustained
inflammatory responses (Elson et al., 1995; Strober et al.,
1998; Boismenu and Chen, 2000). Expression of these
immunomodulatory proteins appear to be regulated mainly
by the transcription factor NF-kB (Baldwin, 1996). In most
cells, NF-kB, a predominant heterodimer consisting of p65
(RelA) and p50 subunits, is present as a latent, inactive, IkB
bound complex in the cytoplasm but upon activation by
extracellular stimuli or by other factors, NF-kB rapidly
Received 28 April 2006; revised 5 June 2006; accepted 28 June 2006;
published online 31 July 2006
Correspondence: Dr PK Das, Molecular Cell Biology Laboratory, Indian
Institute of Chemical Biology, 4 Raja S.C. Mullick Road, Jadavpur, Calcutta
700 032, India.
E-mail: pijushkdas@vsnl.com
British Journal of Pharmacology (2006) 149, 121–131
& 2006 Nature Publishing Group All rights reserved 0007–1188/06 $30.00
www.brjpharmacol.org
translocates to the nucleus and activates gene expression
(May and Ghosh, 1998). The exact molecular mechanism by
which various extracellular stimuli lead to the activation of
NF-kB is not well understood. However, most signals induce
the activity of a large multisubunit protein kinase, called IkB
kinase (IKK). Activation of the IKK complex leads to specific
IkBa phosphorylation/degradation and subsequent release of
NF-kB, which then translocates to the nucleus and activates
transcription of multiple kB-dependent genes including
iNOS and Th1 cytokines. NF-kB has already been shown to
be strongly activated in UC and CD (Neurath et al., 1998;
Rogler et al., 1998; Schreiber et al., 1998). Experimental trials
using p65 antisense oligonucleotides against NF-kB in TNBS-
induced colitis model efficiently prevent NF-kB activation
and cytokine production resulting in the prevention of
mucosal inflammation (Neurath et al., 1996; Hamamoto
et al., 1999). Moreover, compounds which downregulate
NF-kB have been proved to be beneficial in the treatment of
IBD (Sugimoto et al., 2002).
Medications currently available for IBD alleviate inflam-
mation and reduce symptoms, but do not provide a cure or
prevent long-term complications. The principal drugs used
are 5-aminosalicylate, corticosteroids and immunosuppres-
sants. Although these drugs have shown their benefit in the
treatment of IBD, they have serious side effects that limit
their clinical application. Promising treatments that might
be considered as adjuncts to conventional treatment include
herbal medicines derived from plant extracts that are being
utilized to treat a wide variety of clinical diseases. Recently,
there has been a great scientific interest in the field of
phytochemicals, especially tea, as nutritional tools for
chronic disease prevention, a definitive approach to control
disease and reach old age in good health. Tea is consumed
worldwide as black tea, oolong tea and green tea. Although
black tea is the most widely consumed (80% of the total tea
consumption) beverage, the work carried out on black tea
so far is much less compared to green tea. Tea polyphenols
especially catechins of green tea, have been the primary
agent responsible for the beneficial and disease-inhibitory
activity (Dufresne and Farnworth, 2001). During the produc-
tion of black tea, substantial proportions of catechins are
converted to theaflavins and thearubigins by a polyphenol
oxidase (Balentine et al., 1997). Theaflavins (about 1–2%
of the total dry weight of black tea) including theaflavin,
theaflavin-3-gallate (TFD1), theaflavin-30-gallate (TFD2) and
theaflavin-3,30-digallate (TFDG), possess benzotropolone
rings with dihydroxy or trihydroxy systems. Only recently
work has been initiated with black tea or its characteristic
constituents, theaflavins and thearubigins (TR), which have
revealed diverse pharmacotherapeutic effects including
hypoglycemic (Gomes et al., 1995), anticarcinogenic (Mukh-
tar and Ahmad, 2000; Schwab et al., 2000) and antiathero-
sclerotic (Muramatsu et al., 1986) effects. A number of
studies have shown that tea polyphenols especially TFDG,
inhibit production of NO and expression of iNOS mRNA by
murine macrophages (Chan et al., 1997; Kim et al., 1999; Lin
et al., 1999) and this TFDG mediated inhibition of iNOS
is associated with downregulation of NF-kB activation (Lin
et al., 1999). These observations suggest that TFDG may be
useful in the treatment of patients with IBD.
In the present, study we administered TFDG to mice with
TNBS-induced colitis to evaluate its beneficial effects on
intestinal inflammation. Our results demonstrate that treat-
ment with TFDG depends on its ability to suppress the TNBS-
induced activation of NF-kB and increased production of
proinflammatory cytokines such as IL-12, IFN-g and TNF-a.
Methods
Animals
Female BALB/c mice weighing 25–30 g (obtained from
National Institute of Nutrition, Hyderabad, India) were used
for the experiments. Mice were housed under normal
laboratory conditions that is at 21–241C and 40–60% relative
humidity, under a 12 h light/dark cycle with free access to
standard rodent food and water. The investigation conforms
to the Guide for the Care and Use of Laboratory Animals
published by US National Institutes of Health (NIH Publica-
tion No. 85-23 revised 1996) and with the approval of the
Institutional Animal Care and Use Committee.
Experimental colitis
To induce colitis, mice were lightly anesthetized with diethyl
ether and 0.1 ml of TNBS (60 mg ml1 in 30% ethanol), was
slowly administered into the lumen of the colon through a
trochar needle approximately 3–4 cm proximal to the anus
according to the model described earlier (Neurath et al.,
1995). Control group of mice received 30% ethanol in PBS
using the same technique. Animals were killed at 2, 4 and 8
days after TNBS administration. TFDG was administered by
oral gavage in 200 ml of PBS (freshly prepared) every day, over
a 18-day period. To investigate the dosage effect, 1, 2.5, 5 and
10 mg kg1 of TFDG was given daily by oral gavage for 10
days before subjecting the mice to TNBS-induced colitis and
the same dose of TFDG was continued until the mice were
killed 8 days after the induction of colitis (Figure 1). Five
or six animals were used for each time point after TNBS
administration.
Macroscopic assessment of severity of colitis
Mice were killed by cervical dislocation, the colon excised,
opened longitudinally and washed in saline. Macroscopic
damage was assessed by the scoring system of Wallace and
Keenan (1990), which takes into account the area of
inflammation and the presence and absence of ulcers. The
criteria for assessing macroscopic damage was based on a
semi-quantitative scoring system where features were graded
as follows: 0, no ulcer, no inflammation; 1, no ulcer, local
hyperaemia; 2, ulceration without hyperaemia; 3, ulceration
and inflammation at one site only; 4, two or more sites of
ulceration and inflammation and 5, ulceration extending
more than 2 cm. After macroscopic observation, samples of
colonic tissue were subsequently excised for microscopic
observation of damage, measurement of NO and mRNA
expression of cytokines and iNOS.
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Microscopic assessment of colitis
The colon was fixed in 10% formalin in PBS for 1 week and
the samples were then dehydrated in graded ethanol and
embedded in paraffin. Sections 7mm were deparaffinized
with xylene, stained with hematoxylin–eosin and examined
in a Leitz Ortholux microscope. Histologic changes were
graded semi quantitatively from 0 to 4 according to
previously described criteria (Neurath et al., 1995) as follows:
0, no leukocyte infiltration; 1, low level of leukocyte
infiltration; 2, moderate level of leukocyte infiltration; 3,
high vascular density and thickening of colon wall and 4,
transmural leukocyte infiltration, loss of goblet cells, high
vascular density and thickening of the colon wall.
Macrophages
Macrophages were collected by peritoneal lavage from mice
(BALB/c; 20–25 g) given intraperitoneal (i.p.). injection of
0.5 ml of 4% thioglycollate broth 5 days before harvest and
were utilized as described earlier (Basu et al., 1991). The
culture medium consists of RPMI 1640 supplemented with
10 mM HEPES, 100 U ml1 penicillin, 100 mg ml1 streptomy-
cin and 10% FCS. More than 90% of the cell preparation was
identified as macrophages by microscopic observation, and
the macrophages were routinely found to be 495% viable by
Trypan blue exclusion.
NO production
Nitrite production was determined in macrophage culture
medium by the Griess reaction as previously described (Das
et al., 2001). Cell viability was assessed using a MTT-based
colorimetric assay kit (Roche Applied Science, Basel, Switzer-
land) according to manufacturer’s instructions.
Myeloperoxidase activity
Measurement of myeloperoxidase (MPO) activity is used as
a biochemical marker of neutrophil infiltration into gastro-
intestinal tissues (Morris et al., 1989). The MPO activity of
the tissue was determined by the method described earlier
(Ukil et al., 2003).
Analysis of cytokines
The colon was homogenized in ice-cold tissue protein
extraction medium (Pierce, Rockford, IL, USA) containing
PMSF (10 mg ml1), aprotinin (10 mg ml1), leupeptin
(10 mg ml1), N-p-tosyl-L-lysine chloromethyl ketone
(10 mg ml1) and L-1-tosylamido-2-phenylethyl chloromethyl
ketone (10 mg ml1). The homogenate was then centrifuged
at 18 000 g for 20 min at 41C. IFN-g, IL-12 and TNF-a were
measured in the supernatant using an ELISA kit (BD
Biosciences, San Jose, CA, USA). mRNA profiles for these
cytokines along with b-actin as internal control were
analyzed by RT-PCR. Reverse transcription of 1mg of RNA
was performed according to the manufacturer’s protocol for
the Superscript One-Step RT-PCR system (Invitrogen Life
Technologies, Carlsbad, CA, USA). Primers for all these genes
have been published (Kawakami et al., 1997). After the
appropriate number of PCR cycles, the amplified cDNA was
separated by 2% agarose gel electrophoresis and visualized by
ethidium bromide staining.
iNOS expression by RT-PCR and immunoblot analysis
RT-PCR was performed to determine the mRNA profile for
iNOS along with b-actin as internal control. For immunoblot
analysis, 20 mg of colonic extracts were resolved by SDS-
PAGE, electroblotted to nitrocellulose membrane and
probed with murine anti-iNOS antibody (Transduction
Laboratories, Lexington, KY, USA). After extensive washing,
the antigen-antibody complexes were detected by the ECL
kit (Amersham Biosciences, Arlington Heights, IL, USA)
using horseradish peroxidase-conjugated anti-rabbit IgG
(1:2000 dilution).
Preparation of nuclear and cytoplasmic extracts
A modified procedure based on Yang et al. (1998) was
used. Briefly, the excised colons were washed with PBS
(pH 7.4) and homogenized in ice-cold lysis buffer (10 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
PMSF, 0.5 mM dithiothreitol and 1mg ml1 of aprotinin,
leupeptin and pepstatin A), using a Dounce homogenizer.
Homogenates were then incubated on ice for 45 min,
NP-40 was added to a final concentration of 0.5% and the
mixture was centrifuged at 5000 g for 10 min at 41C. The
supernatant was saved for analysis of cytosolic proteins.
The pellet was extracted in nuclear extraction buffer
(20 mM HEPES, pH 7.8, 400 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 25% glycerol, 0.5 mM PMSF, 0.5 mM DTT and
1 mg ml1of aprotinin, leupeptin and pepstatin A) for 30 min
on ice and centrifuged at 15 000 g for 15 min. Protein
concentrations were determined using Bio-Rad protein
assay system (Bio-Rad, Hercules, CA, USA). Extracts were
stored at 801C.
Figure 1 Time course of experimental schedules. Control and
TFDG group received TFDG daily by oral gavage for a total of 18
days. Both TNBS and TFDG group received TNBS by intracolonic
administration at day 10 whereas the control group received 30%
ethanol at day 10. Groups of mice were killed (Sample) at 12, 14 or
18 days after the start of the study.
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Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA), each 10 mg of
nuclear extracts were preincubated with 1mg of poly (dI-dC)
in a binding buffer (25 mM HEPES, pH 7.9, 0.5 mM EDTA,
0.5 mM dithiothreitol, 1% Nonidet P-40, 5% glycerol and
50 mM NaCl) for 10 min at room temperature. As a control, a
50-fold molar excess of unlabeled NF-kB competitor oligo-
nucleotide was added. After preincubation, 0.5 ng of 32P end-
labeled NF-kB oligonucleotide probe (50-CGGGGACTTT
CCGCTGGGGACTTTCCGCTTGAGCT-30) was added to the
reaction mixture and incubated for 30 min. The DNA-protein
complex was then electrophoresed on 4.5% nondenaturing
polyacrylamide gels in 0.5 TBE buffer (0.0445 M Tris,
0.0445 M borate and 0.001 M EDTA). For supershift assay,
the nuclear extracts from TNBS-treated cells were incubated
with antibodies against individual components of NF-kB
complex (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 30 min at 251C and analyzed by EMSA in the presence of
all components of the binding reaction described above. As
controls, the nuclear extracts were also treated with normal
rabbit IgG.
Western blot analysis of IkBa, p65 and p50
The nuclear and cytosolic proteins (30 mg) prepared from
mice colon were resolved by 12% SDS-PAGE and electro-
transferred to nitrocellulose membranes (Schleicher and
Schuell, Keene, NH, USA). Membranes were washed with
Tris-buffered saline (TBS) (100 mM Tris-HCl, 0.9% NaCl, pH
7.5) and immunoblotted as follows. Nonspecific binding
sites were blocked with TBS containing 0.1% Tween 20 (TBS-
T) and 5% nonfat dry milk at room temperature for 18 h.
Membranes were then incubated in a 1:1000 dilution of
rabbit polyclonal anti-IkBa for cytosolic proteins or anti-p50
and anti-p65 antibodies for nuclear proteins (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) in TBS-T. After four
washes in TBS-T, membranes were incubated in a 1:5000
dilution of horseradish peroxidase-conjugate anti-rabbit IgG
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at
room temperature. After washing, immunoreactive proteins
were detected by enhanced chemiluminescence using an
ECL detection kit (Amersham Biosciences, Arlington
Heights, IL, USA). Band intensities were quantitated densi-
tometrically using QUANTITY ONE (Bio-Rad, Hercules,
CA, USA).
IKK assay
The assay was performed as described by Andresen et al.
(2005). 300 mg of cytosol extract were immunoprecipitated
with anti-IKKa/b antibody in immunoprecipitation buffer
(40 mM Tris-HCl, pH 8.0, 500 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 10 mM b-glycerophosphate, 10 mM NaF, 10 mM pNPP,
300 mM Na3VO4, 1 mM benzamidine, 2mM PMSF, 10 mg ml
1
aprotinin, 1mg ml1 leupeptin, 1mg ml1 pepstatin, 1 mM
DTT and 0.1% Nonidet P-40). Immunoprecipitated samples
were incubated with recombinant IkBa (4 mg) in kinase buffer
(20 mM HEPES, pH 7.7, 2 mM MgCl2, 10 mM ATP, 3mCi of [g
32-
p]ATP, 10 mM b-glycerophosphate, 10 mM NaF, 10 mM pNPP,
300 mM Na3VO4, 1 mM benzamidine, 2mM PMSF, 10 mg ml
1
aprotinin, 1 mg ml1 leupeptin, 1 mg ml1 pepstatin and 1 mM
DTT) at 301C for 1 h. The kinase reaction was stopped by
addition of SDS-sample buffer. The sample was resolved by
SDS-PAGE, dried and autoradiographed. To determine the
total amounts of IKKa and IKKb in each sample, 30 mg of the
whole cell extract protein was subjected to SDS-PAGE and
analyzed by Western blot using anti-IKKa and IKKb antibody.
Statistical analysis
Results are expressed as mean7s.d. of n observations.
We used analysis of variance to determine the statistical
significance of inter group comparisons. Po0.05 was
considered to be statistically significant. Macroscopic and
microscopic scores for colonic erosions for the TFDG-
pretreated groups were compared with those for the TNBS-
treated group with a two-sided Wilcoxon rank-sum test.
Materials
TFDG, TFD1, TFD2 and TR were isolated from CTC (curl, tear
and crush) BOP (broken orange pickoe) grade black clonal
tea processed in October 1991 and supplied by Tocklai
Experimental Station, Jorhat, Assam, India (collection No.
01091) according to the method described earlier (Chen and
Ho, 1995). The purity of TFDG was determined to be 498%
by HPLC. TNBS and all other chemicals were purchased from
Sigma Chemical Co., St Louis, MO, USA). Rabbit polyclonal
antibodies for NF-kB p65, p50, IkBa, IKKa and IKKb and
NF-kB consensus oligonucleotide and recombinant IkBa
were purchased from Santa Cruz Biotechnology, Santa Cruz,
CA, USA).
Results
Inhibition of NO generation by tea polyphenols
IBD and animal models of colitis are characterized by high
levels of NO generation by iNOS, which can result in
mucosal injury (Sandborn and Yednock, 2003). As TFDG
might act as a therapeutic agent for IBD through inhibition
of NO production, we first investigated the ability of TFDG
to downregulate NO in LPS-activated murine macrophages.
As shown in Figure 2a, TFDG could downregulate NO
production in peritoneal macrophages in a concentration-
dependent manner. The effect was maximal with a concen-
tration of 40 mM after incubation for 24 h. TFDG exhibited no
cytotoxicity at concentrations up to 50 mM. Furthermore,
when selected polyphenols of black tea were tested for
inhibition of NO, TFDG was found to be the most effective
(Figure 2b), which is in agreement with the earlier observa-
tion by Lin et al. (1999). The level of inhibition by various
polyphenols is also consistent with the expression of iNOS
mRNA, which, after isolation of total RNA, was subjected to
RT-PCR analysis (Figure 2c).
Effect of TFDG on TNBS-induced colitis
As TFDG could downregulate NO production together with
the absence of obvious cytotoxicity on macrophages, we
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checked the efficacy of TFDG on TNBS-induced colitis. Single
intracolonic administration of 6 mg TNBS in 30% ethanol
reproducibly induced a transient IBD-like colitis with
maximum inflammation at 4 days. Significant edema
formation along with focal ulcerations, necrosis and adhe-
sions was observed in the descending colon of the TNBS
control group. The dose titration experiment assessed the
efficacy of TFDG against TNBS-colitis with a dose range of
1–10 mg ml1 given daily for 10 days before induction of
colitis as well as during the course of the disease. Oral
administration of TFDG significantly reduced the extent and
severity of the injury of large intestine in a dose-dependent
manner as shown by both macroscopic and microscopic
damage scores (Figure 3a and e). As expected, TFDG
significantly reduced colonic MPO activity, an index of
neutrophilic infiltration in the mucosa (Figure 3f). TFDG
pretreatment also significantly reversed the decrease of body
weight and increase of spleen and colon weight, an indicator
of inflammation, associated with TNBS-induced colitis
(Figure 3b, c and d). The results indicate that 5 mg kg1 day1
might be regarded as the lowest active dose of TFDG for
effective treatment. Histochemistry demonstrated promi-
nent infiltration of granulocytes into the affected colon of
TNBS control, especially in the most severely damaged
regions (Figure 3h) at day 4. In contrast, in colonic sections
from TFDG-treated mice (5 mg kg1 day1), only a few
granulocytes were observed in the mucosa and submucosa
propria (Figure 3i). Regarding local effects of TFDG in the
colons, control experiments were carried out using TFDG
pretreatment in the absence of TNBS treatment as well as
TFDG pretreatment in 30% ethanol. In both the controls, no
histological modifications were observed as compared to
control mice receiving 30% ethanol.
Effects of TFDG on cytokine mRNA levels
To evaluate the type of immunological response in TNBS-
induced colitis due to TFDG treatment, mRNA transcription
levels for TNF-a, IFN-g and IL-12 p40 were determined on
colonic mucosal cells. The increases in all the cytokine
mRNA levels occurred in TNBS-treated groups from day 2
through day 8 but most significant increases were seen at day
4 compared with control (ethanol-treated) at corresponding
times (Figure 4a). This represented a dominant inflammatory
Th1 response in TNBS-induced colitis. However, pretreat-
ment with TFDG (5 mg kg1 day1) significantly decreased
the message levels in TNBS-treated groups in all the time
points from day 2 through day 8 compared with TNBS-
treated group at corresponding time (Figure 4a). For addi-
tional confirmation, cytokine production was assessed in
colonic mucosal cells of TFDG-treated animals at the protein
level by ELISA, which showed significantly less TNF-a, IFN-g
and IL-12 p40 than those from TNBS control (Figure 4b).
TFDG pretreatment also resulted in downregulation of iNOS
in TNBS-group at both mRNA and protein level (Figure 5).
These results not only suggest suppression of Th1 functions
but also show the potential of TFDG as a proper effector
molecule, which might induce protective responses.
Effect of TFDG on NF-kB DNA binding and activation
The apparent decrease of iNOS and Th1 cytokine profile by
TFDG led us to examine the status of NF-kB in control and
treated mice, because this transcription factor is known to
regulate the production of various proinflammatory cyto-
kines such as IL-12, IL-1b and TNF-a as well as the activation
of specific enzymes such as iNOS and cyclooxygenase. The
kinetics of NF-kB activation in colonic mucosa groups were
determined by EMSA using nuclear extracts of whole colonic
tissues from control mice (which received 30% ethanol
without TNBS) and TFDG-treated or untreated TNBS colitis
Figure 2 Effect of TFDG on NO production. (a) Peritoneal
macrophages (106 cells ml1) were cotreated with LPS (100 ng ml1)
and various concentrations of TFDG for 24 h at 371C. Cell viability
was assessed by an MTT assay. (b) Macrophages (106 cells ml1)
were incubated with LPS (100 ng ml1) either alone or in the
presence of 40mM each of TFDG, TFD1, TFD2 or TR. Each bar shows
the mean7s.d. of three independent experiments. (c) The nature of
iNOS expression by various agents was also determined by RT-PCR
of its mRNA transcript.
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mice (Figure 6a). A basal level of NF-kB DNA-binding activity
was found in colonic nuclear extracts from mice in control
group. The nuclear localization of NF-kB in the TNBS-treated
group was increased after day 2 compared to control group,
became maximal at day 4 and again decreased at day 8.
TNBS-induced enhancement of NF-kB DNA-binding activity
was suppressed by pretreatment with 5 mg kg1 day1 TFDG
at all time points. Excess unlabeled specific oligonucleotides
inhibited the NF-kB mobility shift, indicating thereby the
specificity of DNA-protein complex. To identify the specific
NF-kB subunits that comprise the NF-kB signal detected by
EMSA in TNBS-induced colitis at day 4, supershift assay was
performed. Specific antibodies to p50, p52, p65, c-Rel and
Rel B were used for these experiments. Supershift studies
demonstrated that antibodies to p65 shifted the entire signal
and that antibodies to p50 also caused a significant shift.
However, anti-p52, anti-c-Rel or anti-Rel B antibodies did not
shift the NF-kB signals (Figure 6b). To determine the effect of
TFDG on the migration of p50 and p65 into the nucleus,
Western blot analyses of nuclear protein fractions from
colonic mucosa were conducted. Accumulation of p50 and
p65 subunits in the nuclear protein fraction was greatly
increased in TNBS-treated mice at all time points examined
(Figure 6c). However, consistent with the DNA-binding
Figure 3 Effect of TFDG treatment on established colitis. Mice were treated with 0.1 ml of TNBS (60 mg ml1) intracolonically and assessed at
various times (2–8 days) after treatment. (a) Colonic damage was scored by blinded assessment based on validated scoring system as described
in Methods. Evaluation of body weights (b), spleen (c) and colon (d) expressed as a percentage of the original weight on day 0. A significant
weight gain was observed at 4 days after TNBS administration in spleen and colon. TFDG pretreatment (5 and 10 mg kg1) significantly
prevented the loss in body weight (b) as well as reduced the organ weight (c and d). (e) Histological scoring was performed semi-quantitatively
in hematoxylin and eosin-stained sections. (f) Assessment of myeloperoxidase activity in TNBS-treated mice in comparison to control. Values
are means7 s.d. of 10 mice for each group. Results for the TFDG treatment group were compared against those for the TNBS-treated group
with a two-sided Wilcoxon rank-sum test. *Po0.01, **Po0.05 vs TNBS. Histological appearance of mice colonic mucosa after hematoxylin and
eosin stain, treated with 30% ethanol in PBS (g), treated with TNBS (60 mg ml1) in 30% ethanol (h) and pretreated with TFDG (5 mg kg1)
(i). TNBS-induced colonic inflammation (at 4 days) was mostly associated with loss of goblet cells, crypt damage, mucosal ulceration and
accompanying edema of the submucosa. Pretreatment with TFDG significantly attenuated the damages in morphology associated with TNBS
treatment. Original magnification: 250.
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activity, nuclear translocation of both p50 and p65 subunits,
which peaked at day 4 after TNBS-treatment, were signifi-
cantly suppressed by oral administration of 5 mg kg1 day1
TFDG.
Preservation of IkBa by TFDG pretreatment
The activation of NF-kB is thought to occur secondary to the
proteolytic degradation of cytosolic IkBa, allowing free NF-
kB to translocate to the nucleus where it binds to specific
promoter sequences and initiates gene transcription (Henkel
et al., 1993). As pretreatment with TFDG inhibited NF-kB
activation in colonic mucosa of mice receiving TNBS, we
determined if the protective effect of TFDG against TNBS-
induced colon injury might be related to its effect in
preserving cytosolic IkBa. Western blot analysis of the
cytoplasmic extract prepared from colon homogenates
revealed that IkBa protein levels were elevated in TFDG-
treated group compared with untreated TNBS group
(Figure 7a). Although a basal level of IkBa was there in the
control group (30% ethanol), IkBa protein levels were greatly
depleted in TNBS groups, indicating that NF-kB activation in
this group occurred via IkBa degradation. In contrast,
pretreatment with TFDG (5 mg kg1 day1) in TNBS groups
protected IkBa degradation, which in turn prevented the
translocation of NF-kB from the cytoplasm to nucleus. As
IkBa is phosphorylated by the IKK multiprotein complex, the
effect of TFDG on the status of intrinsic cellular IKK
activation was determined. Accordingly, IKK was isolated
from the colonic mucosal cytosolic extract of TFDG-treated
Figure 4 Proinflammatory cytokine expression in colonic mucosa of mice with TNBS-induced colitis. Oral pretreatment with TFDG
(5 mg kg1) showed a significant decrease in the expression levels of IFN-g, IL-12 p40 and TNF-a in the colon of TNBS-treated mice both at
mRNA (a) and protein (b) level as analyzed by RT-PCR and ELISA, respectively. RT-PCR products were visualized by ethidium staining. RNA
samples were obtained from six mice in each group. Results are representative of three separate samples. b-actin expression levels were used as
controls for RNA content and integrity. Band intensities quantified by densitometry are shown as bar diagrams.
Figure 5 A time–course pattern of iNOS expression. iNOS expression by RT-PCR (a) and Western blot (b) in colonic mucosa of colitic mice
and TFDG-pretreated colitic mice on day 2, 4 and 8 after TNBS administration. RT-PCR products were visualized by ethidium bromide staining.
RNA samples were obtained from six mice in each group. Results are representative of duplicate samples of three separate experiments and the
densitometric evaluations are means of three independent experiments. *Po0.01; **Po0.001 vs control. b-actin expression levels were used as
controls for RNA content and integrity.
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and untreated TNBS-colitic mice by immunoprecipitation
with anti-IKKa and anti-IKKb antibodies. The immunopreci-
pitated samples were used for kinase assay with recombinant
IkBa as substrate. The radiolabeled phosphorylated IkBa-
specific band was detected in mucosal cells of TNBS-treated
mice, demonstrating the ability of TNBS to induce IKK
activity (Figure 7b). In contrast, IKK activity was negligible in
the normal untreated (30% ethanol) as well as TFDG-treated
colitic mice (Figure 7b). Western blot analysis with whole cell
lysates using anti-IKKa and anti-IKKb antibodies (Figure 7b)
showed identical levels of expression of IKK, suggesting that
IKK was equally expressed in cells with different treatments.
These results suggest that oral administration of TFDG
prevented the TNBS-induced NF-kB activation by suppres-
sion of IKK activity resulting in preservation of the cytosolic
IkBa protein. This may, in part, explain the reduced levels of
proinflammatory cytokines in TNBS-treated groups after
TFDG pretreatment.
Discussion and conclusions
Results of the present study have demonstrated that TFDG
treatment could substantially reduce the TNBS-induced
increased levels of inflammation and tissue injury in the
mouse colon. This is consistent with the results reported by
other investigators that the release of NO and proinflamma-
tory cytokines play a central role in the TNBS-induced colitis.
The ability of TFDG treatment to suppress the TNBS-induced
release of these mediators, therefore, may constitute one of
the possible mechanisms for its anticolitic effects. Further,
the present study provides the first in vivo evidence that
TFDG may exert its beneficial effects on experimental colitis
at least in part, by inhibiting the IkBa-dependent signaling
pathway.
Extensive experimental studies have shown that a variety
of the pro-inflammatory mediators associated with IBD are
regulated at the transcriptional level by the nuclear factor
Figure 6 Effects of TFDG pretreatment (5 mg kg1) on the kinetics of NF-kB activation in colon tissue samples of mice with TNBS-induced
colitis. (a) Nuclear extracts were obtained from mouse colon at the indicated time period and analyzed for NF-kB activity by EMSA. Each lane
represents colon nuclear extracts from the control, TNBS or TFDG group. UP indicates 50 molar excess of unlabeled probe. Oral
administration of TFDG consistently decreased the NF-kB-binding activity, which reached maximum at day 4 after TNBS administration and
then started decreasing. (b) For supershift assay, nuclear extracts from colonic mucosa of mice at 4 day after TNBS administration were
incubated with antibodies against individual components of NF-kB complex for 30 min before to EMSA analysis. (c) Western blot analysis of
nuclear protein fraction shows a time-dependent migration of p50 and p65 into the nucleus of colon tissues in TNBS-induced colitis. Oral
administration of TFDG (5 mg kg1 day1) markedly suppressed the TNBS-induced nuclear transmigration. The blots were analyzed
densitometrically and are normalized to b-actin. The results are representative of duplicate samples of three separate experiments and the
densitometric evaluations are means of three independent experiments. *Po0.01; **Po0.001 vs control.
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NF-kB and/or activator protein 1 (AP-1) (Karin et al., 1997;
Baeuerle, 1998). Increasing amounts of evidence are avail-
able to show that chronic inflammation of the intestine
and colon can be ameliorated by the inhibition of NF-kB
in experimental colitis (Togawa et al., 2002). Inhibition of
NF-kB in peripheral blood mononuclear cells and lamina propria
mononuclear cells has been shown to offer an interesting
alternative approach for the treatment of CD (Segain et al.,
2000). A few reports have also demonstrated a role for AP-1
activation in intestinal inflammation (Gonsky et al., 1998;
Abreu-Martin et al., 1999). In a recent study, treatment of
TNBS induced experimental colitis with poly (ADP-ribose)
polymerase inhibitor resulted in reduced DNA-binding of
both NF-kB and AP-1 in the colon (Zingarelli et al., 2003).
Although TFDG is known to inhibit the activation of both
NF-kB and AP-1 (Chung et al., 1999; Lin et al., 1999), in the
present study, we have focused on the mechanism of NF-kB
activation in relation to the pharmacological effect of TFDG.
In our previous study, we reported the protective effect of
thearubigin in TNBS-induced colon injury in mice (Maity
et al., 2003) and suggested that inhibition of NF-kB-regulated
transcriptional control of proinflammatory cytokines may be
an important target for the treatment of IBD. Theaflavins
and thearubigins are known to be the major polyphenols of
black tea. They have phenol rings that act as electron traps to
scavenge peroxy radicals, superoxide-anions and hydroxyl
radicals (Katiyar et al., 1993; Lin et al., 1996). Among
theaflavins, TFDG, which has two gallic acid moieties,
exhibited the strongest anti-inflammatory activity as judged
by its suppression on iNOS induction in LPS-stimulated
macrophages. The inhibition of iNOS protein induction
was in the following order: TFDG4() epigallocatechin-3-
gallate4a mixture of theaflavin-3-gallate and theaflavin-30-
gallate4thearubigin4theaflavin (Lin et al., 1999). Our
results are also in agreement with this order.
The data presented in this report suggest that TFDG exerts
its beneficial effect on TNBS-induced colitis mostly through
its ability to inhibit the activation of NF-kB by inhibiting the
phosphorylation and subsequent degradation of IkBa. The
study is consistent with the findings that TFDG may exert its
anti-inflammatory and cancer chemopreventive actions
by suppressing the activation of NF-kB through inhibition
of IKK activity (Pan et al., 2000; Liang et al., 2002). The
degree of inflammation and tissue injury caused by TNBS
was substantially reduced in mice treated with a dose of
5 mg kg1 day1 TFDG. This dose of TFDG may be correlated
to an average consumption of four cups of tea per day for
a 70-kg adult human as according to Lodovici et al. (2000).
There is ample evidence from animal models of IBD that
NO is involved in gut inflammation through the modulation
of iNOS (Rachmilewitz et al., 1995; Singer et al., 1996; Kimura
et al., 1997). Selective inhibition of iNOS can significantly
decrease the extent and severity of tissue injury in experi-
mental colitis (Kankuri et al., 2001). The data presented in
this paper confirm that oral administration of TFDG down-
regulates the TNBS-induced overexpression of proinflamma-
tory cytokine genes for IFN-g, IL-12, TNF-a and also iNOS.
TFDG treatment led to a marked suppression in IL-12 mRNA
levels by mucosal cells of TNBS-administered mice, which
may result in reduced Th1 response as IL-12 production is
critical for the development of Th1 cells (Trinchieri, 1998). A
growing body of literature is available on the beneficial effect
of EGCG, the most effective polyphenol component of green
tea, on various disease processes and health disorders.
Although limited studies have been carried out with black
tea, most of the biological functions of tea polyphenols have
been ascribed to their antioxidation activity and theaflavins
in black tea possess at least the same antioxidant potency as
catechins in green tea (Leung et al., 2001). Thus, both EGCG
and TFDG are known to inactivate PKC (Chen et al., 1999)
Figure 7 Effect of TFDG pretreatment on IkBa protein expression and IKK activation in the colon tissue of mice with TNBS-induced colitis.
(a) Western blot analysis shows a time dependent increased preservation of IkBa protein in TFDG (5 mg kg1 day1) pretreated groups as
opposed to depletion in TNBS groups. The blots were analyzed densitometrically and the values are normalized to b-actin. Results are
representative of one of three independent experiments. (b) Whole cell extracts were prepared and immunoprecipitated with antibodies
against IKKb and IKKa. Activity of immunoprecipitated IKK was measured using GST-IkBa as substrate and GST phosphorylated-IkBa was
visualized by autoradiography. Relative amounts of IKKa and IKKb in the whole cell extracts were determined by Western blots.
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and have also been shown to block the induction of NOS
(Lin et al., 1999). Moreover, antitumor promotion effects
of EGCG and TFDG may be functionally linked to the
inhibition of signal transduction to transcription factors
such as AP-1 and NF-kB (Nomura et al., 2000).
The mechanism by which TFDG inhibits iNOS, IL-12 and
TNF-a production seems to be through the downregulation
of NF-kB-mediated activation, since TFDG is capable of
inhibiting NF-kB activity in EMSA using nuclear extracts of
colonic cells. As NF-kB activation is believed to play a major
role in regulation of proinflammatory gene transcription, its
suppression by TFDG may inhibit early steps of inflamma-
tion and modulate upregulation of multiple proinflamma-
tory genes. Binding sites for the NF-kB family of
transcription factors are found in the promoter and
enhancer regions of a multitude of genes, including
cytokines, chemokines and growth factors that are known
to be involved in the inflammatory response. Our data
suggest that activation and nuclear translocation of NF-kB
is important for TNBS-induced colon injury in mice. The
accumulation of p65 and p50 in the nuclear fraction of
TNBS-treated mice, were significantly decreased in TFDG-
pretreated mice. Our findings also support a role for IKBa
in vivo because activation of NF-kB during TNBS-induced
colitis was accompanied by depletion of IkBa from the
colonic tissue, presumably though proteolytic degradation.
The data presented in this study thus strongly suggest that
activation of NF-kB in vivo is a necessary prerequisite for the
production of proinflammatory cytokines in TNBS-induced
colitis and the protection afforded by TFDG may be due to its
antioxidant effects. This is consistent with the observation of
other in vitro and in vivo studies where treatments with
antioxidants such as N-acetyl cysteine (Leff et al., 1993) and
pyrrolidine dithiocarbamate (Nathens et al., 1997) were
found to block activation of NF-kB by blocking the signal-
induced phosphorylation of IkBa.
In conclusion, this study demonstrates that the degree
of colitis caused by administration of TNBS is significantly
attenuated by TFDG, a major polyphenol of black tea.
Further, we have provided evidence that the activation of
transcription factor NF-kB plays a significant role in TNBS-
induced colitis and the therapeutic potential of TFDG resides
in its ability to downregulate the activation of NF-kB
by inhibiting the degradation of its endogenous inhibitor
IkBa. TFDG thus may be used as a downregulator of NF-kB
transactivation and might prove to be therapeutically
effective for the treatment of inflammation in general.
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